Hi Pinton72,
Thanks for sharing.
Interesting first drug to market comparison with Oleogel-s10.
Amrty Pharma 's Oleogel-s10 is interesting one; Epidermolysis Bullosa seems to effect in US 1 in 30,000 to 50,000 and approx 500k population world wide, although swift uptake expected peak sales are expected to be US $256m approx another suggesting EU $140m and another suggesting it could become a $1bn product;
Based on this on face value and admittedly small amount of research, given Trofitide has Peak sales US at $500m and assumed the same in ROW = $1bn peak sales globally...Hashan Disilva noted in his coverage Trofinitide was $1.1bn total sales product conservatively in US, globally $2.2bn conservatively.
This deal for Amrty Pharma was for $1.5bn based on a half of our estimated US Peaks Sales or a quarter of our assumed global potential peak sales.
Is Neu worth $6bn for Trofinitide?
The exact prevalence of epidermolysis bullosa simplex is unknown, but this condition is estimated to affect 1 in 30,000 to 50,000 people.
https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwjHnZKen7v8AhVc8TgGHdiZBR0QFnoECBEQAQ&url=https%3A%2F%2Fwww.clinicaltrialsarena.com%2Fcomment%2Famryts-oleogel-s10-approvable-in-epidermolysis-bullosa%2F&usg=AOvVaw0ajGU4QEI_OTbmG7DgQkrS
https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwizydblprv8AhVs7zgGHX4iCDAQFnoECA4QAQ&url=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Ffilsuvezs-european-approval-adds-growth-165424701.html&usg=AOvVaw1ICyKWMbvoj9Et6VP9XIce
https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwizydblprv8AhVs7zgGHX4iCDAQFnoECBIQAQ&url=https%3A%2F%2Fpharmaphorum.com%2Fnews%2Ffda-turns-down-amryts-epidermolysis-bullosa-drug%2F&usg=AOvVaw1WixRcbx3nXulCkpFqaoy2
- Forums
- ASX - By Stock
- Share Price
Hi Pinton72,Thanks for sharing. Interesting first drug to market...
-
- There are more pages in this discussion • 7,610 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B |
Open | High | Low | Value | Volume |
$20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1378 | $21.24 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$21.29 | 218 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200 | 21.240 |
1 | 47 | 21.150 |
1 | 500 | 20.860 |
1 | 240 | 20.800 |
1 | 50 | 20.630 |
Price($) | Vol. | No. |
---|---|---|
21.300 | 12763 | 1 |
21.350 | 30 | 1 |
21.380 | 471 | 1 |
21.410 | 25 | 1 |
21.500 | 60 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online